Stock listing

Shanghai:688321 Shenzhen Chipscreen Biosciences Co. Ltd. (微芯生物) 股价

Follow Shenzhen Chipscreen Biosciences Co. Ltd. into a list and get an email when it puts out news.

Share price · SSE:688321

¥16.54 CNY -2.20 (-11.7%)

Close on Nov 20, 2026

Past year -40.0% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
¥16.52 – ¥17.60 CNYNov 20, 2026
Volume
10.09M sharesNov 20, 2026
Market cap
¥7.33B CNYAt the close on Nov 20, 2026 · price × 442.9M shares outstanding
52-week range
¥16.52 – ¥36.47 CNYLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
¥196.2M CNYMedian day 7.06M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Shenzhen Chipscreen Biosciences Co. Ltd. logo

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · SSE:688321 · CNY, adjusted for splits

DayCloseChange%OpenHighLowVolume
¥16.54-2.20-11.7%¥17.31¥17.60¥16.5210,093,450
¥18.74-0.36-1.9%¥19.09¥19.27¥18.307,585,843
¥19.10-0.60-3.0%¥19.73¥19.84¥19.006,566,484
¥19.70-0.53-2.6%¥20.25¥20.43¥19.625,647,092
¥20.23-0.93-4.4%¥21.20¥21.38¥20.145,923,702
¥21.16-0.18-0.8%¥21.34¥21.59¥21.124,977,748
¥21.34+0.09+0.4%¥21.24¥21.38¥20.894,387,661
¥21.25+0.25+1.2%¥21.31¥21.37¥21.004,362,056
¥21.00-0.12-0.6%¥21.46¥21.48¥21.004,307,021
¥21.12-0.27-1.3%¥20.96¥21.58¥20.795,953,549
¥21.39+0.59+2.8%¥20.80¥21.64¥20.718,086,007
¥20.80+1.02+5.2%¥19.92¥20.95¥19.789,642,083
¥19.78-0.32-1.6%¥20.07¥20.28¥19.656,576,739
¥20.10+0.24+1.2%¥19.93¥20.22¥19.418,802,066
¥19.86-0.29-1.4%¥20.00¥20.96¥19.738,147,307
¥20.15-0.40-1.9%¥20.33¥20.44¥19.778,226,868
¥20.55-0.97-4.5%¥21.20¥21.36¥19.8013,090,314
¥21.52-1.02-4.5%¥22.70¥22.88¥21.515,989,554
¥22.54-0.14-0.6%¥22.65¥22.82¥22.224,366,426
¥22.68+0.50+2.3%¥22.02¥22.80¥21.467,879,513
¥22.18-0.41-1.8%¥22.60¥23.46¥22.186,686,907
¥22.59+0.21+0.9%¥22.58¥23.03¥22.454,355,699
¥22.38+0.59+2.7%¥21.80¥22.45¥21.575,555,893
¥21.79-0.010.0%¥21.64¥22.10¥21.435,217,661
¥21.80-0.13-0.6%¥22.34¥22.77¥21.567,188,528
¥21.93-0.03-0.1%¥21.77¥22.50¥21.456,784,305
¥21.96-0.84-3.7%¥22.66¥22.87¥21.966,328,870
¥22.80-0.82-3.5%¥23.48¥23.48¥22.318,753,373
¥23.62-0.69-2.8%¥24.40¥24.49¥23.525,838,755
¥24.31+0.25+1.0%¥23.97¥24.45¥23.568,494,908
¥24.06-1.16-4.6%¥25.30¥25.62¥23.9010,864,125
¥25.22+0.30+1.2%¥24.85¥25.85¥24.858,068,655
¥24.92-0.29-1.2%¥25.22¥25.73¥24.836,160,112
¥25.21-0.14-0.6%¥25.40¥25.59¥24.827,812,107
¥25.35-0.83-3.2%¥26.10¥26.37¥25.188,665,653
¥26.18-0.13-0.5%¥26.54¥26.62¥26.157,537,794
¥26.31+0.08+0.3%¥26.10¥26.70¥26.0010,630,933
¥26.23+1.21+4.8%¥25.26¥26.64¥25.2016,674,198
¥25.02+0.44+1.8%¥24.79¥25.18¥24.636,927,445
¥24.58+0.14+0.6%¥24.40¥24.94¥24.405,418,164
¥24.44+0.39+1.6%¥24.02¥24.49¥23.945,492,343
¥24.05-0.22-0.9%¥24.26¥24.44¥24.002,946,104
¥24.27+0.59+2.5%¥23.60¥24.35¥23.465,829,546
¥23.68-0.82-3.3%¥24.48¥24.48¥23.448,837,354
¥24.50-0.43-1.7%¥24.91¥24.91¥24.246,069,964
¥24.93-0.48-1.9%¥25.30¥25.39¥24.886,496,697
¥25.41+0.06+0.2%¥25.35¥25.52¥25.106,340,392
¥25.35+0.17+0.7%¥25.35¥25.53¥25.005,003,315
¥25.18-0.11-0.4%¥25.55¥25.75¥25.106,768,989
¥25.29+0.42+1.7%¥25.10¥25.44¥24.926,567,104
¥24.87-0.60-2.4%¥25.40¥25.48¥24.8210,407,044
¥25.47+0.05+0.2%¥25.39¥25.65¥25.147,387,803
¥25.42-0.41-1.6%¥25.51¥25.60¥25.039,417,644
¥25.83-0.36-1.4%¥26.17¥26.52¥25.808,167,332
¥26.19+0.44+1.7%¥25.76¥26.19¥25.2510,674,113
¥25.75-0.13-0.5%¥25.80¥26.35¥25.549,854,377
¥25.88-0.010.0%¥25.78¥26.09¥25.2511,880,348
¥25.89-2.06-7.4%¥27.87¥28.03¥25.8420,469,750
¥27.95-2.00-6.7%¥29.59¥29.95¥27.8320,890,261
¥29.95+1.09+3.8%¥30.30¥31.88¥29.7028,135,821
Ticker
Shanghai:688321
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Shanghai
Currency
CNY

What changed lately

Latest news

All Shenzhen Chipscreen Biosciences Co. Ltd. news

Shenzhen Chipscreen Biosciences Co. Ltd. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
66 in the last 12 months · 86 in all · newest Nov 18, 2026 · oldest 2025

Valuation

P/E 102× against a median of 14.6×: the highest of 2 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
¥7.32B CNY
P/E
102×
EV/sales
6.8×
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
2.9×
Gross margin
97.5%
Operating margin
11.1%
Net margin
6.6%
Debt to equity
0.5×
Beta
No index for this market yet

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Shenzhen Chipscreen Biosciences Co. Ltd. Class A · SSE:688321US$1.10BUS$1.10B102×6.8×n/a2.9×6.6%0.5×n/a
D&D Pharmatech Co., Ltd. · KRX:347850US$1.15BUS$1.12Bn/a549×n/a11.5×−785.5%0.8×n/a
Structure Therapeutics, Inc. · NASDAQ:GPCRUS$1.15B−US$82.92Mn/an/an/a0.9×n/a0.0×1.38
COMPASS Pathways Plc · NASDAQ:CMPSUS$1.14BUS$747.8Mn/an/an/a8.0×n/a0.4×1.65
Ascentage Pharma Group International · HKEX:6855US$1.11BUS$1.14Bn/a13.6×n/a13.3×−216.5%3.8×n/a
Pharma Mar SA · BME:PHMUS$1.10BUS$978.5M14.6×3.8×16.6×4.2×28.8%0.3×n/a
Alpha Tau Medical Ltd · NASDAQ:DRTSUS$1.09BUS$1.00Bn/an/an/a55.3×n/a0.8×1.89
Kardigan, Inc. · NASDAQ:KARDUS$1.08BUS$621.1Mn/an/an/a1.9×n/a0.0×n/a
PYC Therapeutics Limited · ASX:PYCUS$1.07BUS$775.8Mn/an/an/a2.3×n/a0.0×n/a
Jade Biosciences, Inc. · NASDAQ:JBIOUS$1.06BUS$583.6Mn/an/an/a2.3×n/a0.0×1.14
MedinCell SA · EURONEXT:MEDCLUS$1.05BUS$1.02Bn/a38.4×n/a313×−128.9%18.7×n/a
Median of the othersUS$1.09BUS$877.2M14.6×26.0×16.6×6.1×−172.7%0.3×1.52

Forecasts

Analysts' consensus from EODHD, read Nov 9, 2026. Not 6ix's view and not investment advice.

Price target
32.68 CNY · Analysts' mean
Revenue, year to Dec 2024
706M · 1 analyst

Events

QuarterResultsShare move
Q2 2023Aug 11, 2023 · Before open−0.6%
Q1 2023Apr 27, 2023 · After close−9.1%
Q4 2022Feb 27, 2023 · Before open−1.1%
Q3 2022Oct 28, 2022 · Before open−4.6%
Q2 2022Aug 22, 2022 · After close−6.0%
Q1 2022Apr 29, 2022 · Before open+4.7%
Q4 2021Feb 25, 2022 · After close+2.1%
Quarter to Sep 30, 2021Oct 29, 2021 · Before open+0.1%
Quarter to Jun 30, 2021Aug 29, 2021 · After close−2.2%
Quarter to Mar 31, 2021Apr 30, 2021 · Before open−1.4%
All 11 quarters
QuarterResultsShare move
Quarter to Dec 31, 2020Feb 26, 2021 · Before open+0.5%

Open Events

Financings

RaiseDate
Private placement of a-shares
Update: private placement
Dec 3, 2025

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in CNY

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue909.5M657.9M523.7M529.9M430.4M269.5M173.8M147.7M110.5M85.4M
Cost of revenue117.2M87.5M57.0M30.0M21.6M13.5M7.29M5.51M5.33M2.17M
Gross profit909.5M570.5M466.7M499.9M408.9M256.0M166.5M142.2M105.2M83.2M
Research and development221.6M214.5M270.4M163.7M130.0M92.3M51.4M43.2M37.6M32.4M
Selling, general and administrative262.3M77.3M80.0M71.2M75.0M45.2M32.3M27.3M19.2M21.6M
Operating income50.9M-178.5M97.1M16.0M22.3M37.0M21.7M32.6M24.5M2.03M
Depreciation and amortization70.0M59.0M45.6M38.7M19.6M11.1M4.81M4.34M4.38M3.71M
EBITDA120.9M-119.5M142.7M54.7M41.9M48.1M26.5M37.0M28.9M5.74M
Interest expense35.7M34.2M34.9M20.3M4.86M1.06M1.54M573.3K02.43M
Income before tax50.8M-96.7M97.0M15.2M18.6M36.2M20.7M32.2M23.7M5.24M
Income tax-232.4K17.9M47.8M2.34M-3.36M5.12M1.31M1.00M-416.5K
Net income51.1M-114.6M88.8M17.5M22.0M31.0M19.4M31.2M24.1M5.24M
Earnings per share, basic0.13-0.280.220.040.050.080.050.090.070.02

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents347.6M375.2M375.4M508.6M300.2M318.7M376.1M131.3M102.5M108.6M
Short-term investments295.3M94.1M216.7M291.1M82.1M261.9M4.02M41.8M167.9M101.5M
Receivables287.0M178.4M221.5M154.8M122.9M41.5M81.3M50.4M30.2M-104.2M
Inventory57.7M40.8M47.1M28.5M15.4M12.4M11.0M8.45M9.17M3.84M
Current assets1.18B1.08B1.13B1.18B638.8M769.1M1.07B233.5M310.8M226.0M
Property, plant and equipment699.0M586.3M380.0M281.5M183.1M47.2M
Total assets3.65B3.25B3.20B2.90B1.89B1.73B1.69B716.3M656.0M403.1M
Accounts payable3.78M2.19M9.03M323.5K2.23M3.54M221.9K69.2K3.94M80.6K
Current liabilities843.9M451.3M390.8M540.5M293.8M146.9M137.3M81.5M76.7M111.6M
Long-term debt1.04B1.09B899.2M598.0M4.88M22.8M36.9M87.5M65.0M30.0M
Total debt1.20B1.04B810.1M151.5M60.0M104.8M87.5M75.0M30.0M
Total liabilities-1.66B1.67B1.49B1.32B476.8M232.4M245.1M239.4M205.5M189.7M
Shareholders' equity1.66B1.58B1.59B1.52B1.42B1.49B1.45B476.9M450.6M213.4M
Shares outstanding408.0M408.0M408.3M406.6M409.7M410.1M376.4M359.9M348.7M330.0M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations97.0M76.1M-143.2M43.3M124.8M93.6M-24.6M22.8M2.73M59.8M
Capital spending-178.6M-268.5M-229.0M-400.2M-288.5M-336.3M-133.0M-140.7M-132.8M-65.8M
Free cash flow-81.6M-192.4M-386.3M-356.9M-163.7M-242.6M-157.6M-118.0M-130.1M-6.04M
Cash from investing-296.0M-389.1M-801.7M-30.6M-108.7M-721.5M-13.3M-196.1M-135.6M
Cash from financing175.4M382.6M861.3M-63.3M-45.4M950.2M18.0M192.2M141.6M
Dividends paid-31.7M-27.6M-18.7M-12.2M-4.22M-3.28M-1.48M-549.9K-2.32M-3.49M
Share buybacks-15.0M-3.80M-155.5M
Change in cash-222.5M-44.1M-148.6M115.1M28.6M-64.5M204.8M28.8M-3.43M68.1M

Open Financials

Filings

FilingDateTypeFiled with
(688321)"Shenzhen Chipscreen Biosciences Co., Ltd."Announcement on Initial Repurchase of Shares through Call AuctionNov 18, 2026Other filingsShanghai Stock Exchange
(688321)"Shenzhen Chipscreen Biosciences Co., Ltd."Announcement on Not Revising the Conversion Price of "Chipscreen Convertible Bonds" DownwardNov 17, 2026FinancingShanghai Stock Exchange
(688321)"Shenzhen Chipscreen Biosciences Co., Ltd."Announcement on Voluntary Disclosure of the Renewed Inclusion of the Company's Product in the National Reimbursement Drug ListNov 16, 2026Other filingsShanghai Stock Exchange
(688321)"Shenzhen Chipscreen Biosciences Co., Ltd."Announcement on Voluntary Disclosure of Acceptance of Clinical Trial Application for CS231295 TabletsNov 14, 2026Operations updateShanghai Stock Exchange
(688321)"Shenzhen Chipscreen Biosciences Co., Ltd."Indicative Announcement on "Chipscreen Convertible Bonds" Expected to Meet Conditions for Revising Conversion PriceNov 10, 2026FinancingShanghai Stock Exchange
(688321)"Shenzhen Chipscreen Biosciences Co., Ltd."Announcement on Shareholdings of Top 10 Shareholders and Top 10 Shareholders Holding Unrestricted Shares Concerning Share RepurchaseNov 10, 2026Other filingsShanghai Stock Exchange
(688321)"Shenzhen Chipscreen Biosciences Co., Ltd."Announcement on Share Repurchase Proposal through Call Auction and Receipt of Commitment Letter for Special Loan for Share Repurchase from Financial InstitutionNov 6, 2026Other filingsShanghai Stock Exchange
(688321)"Shenzhen Chipscreen Biosciences Co., Ltd."Announcement on Resolutions of the 32nd Meeting of the 3rd Board of DirectorsNov 6, 2026Meeting outcomeShanghai Stock Exchange
(688321)"Shenzhen Chipscreen Biosciences Co., Ltd."Announcement on Proposal from the Chairman for Share RepurchaseOct 30, 2026Other filingsShanghai Stock Exchange
(688321)"Shenzhen Chipscreen Biosciences Co., Ltd."Report for Q3 2026Oct 28, 2026Quarterly reportShanghai Stock Exchange
All 84 filings
FilingDateTypeFiled with
(688321)"Shenzhen Chipscreen Biosciences Co., Ltd."Announcement on Signing of Project Cooperative Development Agreement and Related Party TransactionsOct 22, 2026Material contractShanghai Stock Exchange
(688321)"Shenzhen Chipscreen Biosciences Co., Ltd."Announcement on Convening the Q3 2026 Performance BriefingOct 21, 2026Meeting noticeShanghai Stock Exchange
(688321)"Shenzhen Chipscreen Biosciences Co., Ltd."Announcement on Voluntary Disclosure of Receipt of the Drug Clinical Trial Approval Notice for NW001Oct 17, 2026Operations updateShanghai Stock Exchange
(688321)"Shenzhen Chipscreen Biosciences Co., Ltd."Announcement on Voluntary Disclosure of Acceptance of Clinical Trial Application for CS23546 TabletsOct 15, 2026Operations updateShanghai Stock Exchange
(688321)"Shenzhen Chipscreen Biosciences Co., Ltd."Announcement on Voluntary Disclosure of Receipt of the Clinical Trial Approval Notice for CS43158 TabletsOct 13, 2026Operations updateShanghai Stock Exchange
(688321)"Shenzhen Chipscreen Biosciences Co., Ltd."Announcement on Conversion Results of Convertible Bonds and Share ChangesOct 9, 2026Operations updateShanghai Stock Exchange
"Shenzhen Chipscreen Biosciences Co., Ltd."Announcement on Listing and Trading of Restricted Shares from 2024 Private Placement of SharesAug 25, 2026FinancingShanghai Stock Exchange
"Shenzhen Chipscreen Biosciences Co., Ltd."Special Report on the Deposit, Management and Actual Use of Raised Funds for the First Half of 2026Aug 19, 2026Other filingsShanghai Stock Exchange
"Shenzhen Chipscreen Biosciences Co., Ltd."Announcement on Convening the 2026 Semi-annual Performance BriefingAug 12, 2026Meeting noticeShanghai Stock Exchange
"Shenzhen Chipscreen Biosciences Co., Ltd."Announcement on Voluntary Disclosure Regarding Acceptance of Clinical Trial Application for NW001Aug 5, 2026Operations updateShanghai Stock Exchange
"Shenzhen Chipscreen Biosciences Co., Ltd."Announcement on Adjustment of Related Matters for the 2026 Restricted Share Incentive PlanAug 4, 2026Other filingsShanghai Stock Exchange
"Shenzhen Chipscreen Biosciences Co., Ltd."Self-inspection Report on Trading in the Company's Shares by Insiders with Access to Inside Information in Relation to the 2026 Restricted Share Incentive PlanJul 31, 2026Legal or regulatory actionShanghai Stock Exchange
"Shenzhen Chipscreen Biosciences Co., Ltd."Announcement on Voluntary Disclosure of Acceptance of Clinical Trial Application for CS43158 TabletsJul 30, 2026Operations updateShanghai Stock Exchange
"Shenzhen Chipscreen Biosciences Co., Ltd."Review Opinion and Statement on the Public Disclosure of the List of Participants for the Initial Grant under the Company's 2026 Restricted Share Incentive Plan Issued by the Remuneration and Appraisal Committee of the Board of DirectorsJul 26, 2026Other filingsShanghai Stock Exchange
"Shenzhen Chipscreen Biosciences Co., Ltd."Announcement on Implementation Result of Shares Repurchase and Share ChangesJul 16, 2026Other filingsShanghai Stock Exchange
"Shenzhen Chipscreen Biosciences Co., Ltd."Notice on Convening the 1st Extraordinary General Meeting in 2026Jul 15, 2026Meeting noticeShanghai Stock Exchange
"Shenzhen Chipscreen Biosciences Co., Ltd."Announcement on Conversion Result of Convertible Bonds and Share ChangesJul 1, 2026FinancingShanghai Stock Exchange
Announcement on Follow-up Credit Rating Results of "Chipscreen Convertible Bonds"Jun 26, 2026FinancingShanghai Stock Exchange
Announcement on Progress in Repurchasing SharesJun 1, 2026Other filingsShanghai Stock Exchange
Indicative Announcement on Report on Results of Shareholders' Inquiry Transfer and Equity Change of Shareholders with Over 5% Shares Reaching 5% Integer MultipleMay 22, 2026Other filingsShanghai Stock Exchange
Indicative Announcement on Pricing for Shareholders' Inquiry-based TransferMay 18, 2026Other filingsShanghai Stock Exchange
Shareholders' Inquiry Transfer PlanMay 15, 2026Acquisition or disposalShanghai Stock Exchange
Announcement on Voluntary Disclosure of Approval of Chiglitazar Sodium for Market Release by the Pharmaceutical Administration Bureau, Macao SARMay 14, 2026Operations updateShanghai Stock Exchange
Announcement on Receipt of the "Decision on the Examination of an Invalidity Declaration Request" from the China National Intellectual Property AdministrationMay 8, 2026Legal or regulatory actionShanghai Stock Exchange
Announcement on Adjusting the Conversion Price of "Chipscreen Convertible Bonds" Due to the Implementation of the 2025 Annual Profit Distribution and Resumption of Trading After Conversion SuspensionMay 7, 2026Trading halt or suspensionShanghai Stock Exchange
Announcement on Convening the Q1 2026 Performance BriefingApr 30, 2026Meeting noticeShanghai Stock Exchange
Report for Q1 2026Apr 29, 2026Quarterly reportShanghai Stock Exchange
Indicative Announcement on the Adjustment of Convertible Bond Conversion Prices and Continuous Suspension for Convertible Shares during the Implementation of 2025 Annual Dividend DistributionApr 28, 2026Trading halt or suspensionShanghai Stock Exchange
Announcement on Resolutions of the 2025 Annual General MeetingApr 20, 2026Meeting outcomeShanghai Stock Exchange
Announcement on Conversion Result of Convertible Bonds and Share ChangesApr 1, 2026Operations updateShanghai Stock Exchange
Announcement on Resolutions of the 25th Meeting of the 3rd Board of DirectorsMar 30, 2026Other filingsShanghai Stock Exchange
Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Clinical Trials of Siglitazone Sodium and Metformin Hydrochloride Extended-Release TabletsMar 16, 2026Operations updateShanghai Stock Exchange
Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Clinical Trials of CS08399 TabletsMar 13, 2026Other filingsShanghai Stock Exchange
Announcement on Initially Repurchasing the Company's Shares through Call AuctionMar 11, 2026Other filingsShanghai Stock Exchange
Announcement on Obtaining Letter of Commitment for Special Loans for Stock Repurchase from Financial InstitutionMar 10, 2026FinancingShanghai Stock Exchange
Announcement on Adjustment of the Conversion Price and Trading Suspension/Resumption of "Chipscreen Convertible Bonds" Due to Private Placement of SharesMar 3, 2026Trading halt or suspensionShanghai Stock Exchange
Announcement on the Chairman's Proposal to Repurchase SharesFeb 27, 2026Other filingsShanghai Stock Exchange
Announcement on Preliminary Earnings Estimate for 2025Feb 26, 2026ResultsShanghai Stock Exchange
Announcement on Signing Tripartite Supervision Agreement for Deposit of Raised Fund in Special AccountFeb 25, 2026Other filingsShanghai Stock Exchange
Announcement on Execution of a License and Distribution Agreement with NizhpharmFeb 3, 2026Other filingsShanghai Stock Exchange
Announcement on the Thawing of Partially Frozen Shares Held by a Shareholder Owning 5% or More of the Company’s EquityJan 30, 2026Other filingsShanghai Stock Exchange
Announcement on Proposed Participation of Connected Persons in the Subscription of Shares Issued to Specific Objects and Related Party TransactionJan 29, 2026Other filingsShanghai Stock Exchange
Announcement on Earnings Preannouncement for 2025Jan 26, 2026GuidanceShanghai Stock Exchange
Indicative Announcement on "Chipscreen Convertible Bonds" Expected to Meet Conditions for RedemptionJan 22, 2026FinancingShanghai Stock Exchange
Announcement on Estimated Amount of Daily Related Party Transactions in 2026Jan 15, 2026Other filingsShanghai Stock Exchange
Prospectus for Issuance of A-shares to Specific Objects in 2024 (Registration Draft)Jan 14, 2026Offer documentShanghai Stock Exchange
Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Clinical Trials of Chiauranib CapsulesJan 8, 2026Operations updateShanghai Stock Exchange
Announcement on Voluntary Disclosure of Approval of Chidamide for Market Release by the Pharmaceutical Administration Bureau, Macao SARJan 7, 2026Other filingsShanghai Stock Exchange
Announcement on Voluntary Disclosure of Acceptance of the Clinical Trial Application for Chiglitazar Sodium Sustained-release TabletsJan 5, 2026Other filingsShanghai Stock Exchange
Announcement on Voluntary Disclosure on the Acceptance of the Clinical Trial Application for CS08399 TabletsDec 31, 2025Other filingsShanghai Stock Exchange
Announcement on Implementation Result of Shares Repurchase and Share ChangesDec 23, 2025ResultsShanghai Stock Exchange
Announcement on Voluntary Disclosure of the Inclusion of the Company’s Product in the National Medical Insurance CatalogDec 7, 2025Other filingsShanghai Stock Exchange
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025Dec 5, 2025Meeting noticeShanghai Stock Exchange
Announcement on Obtaining Reply of Registration Approval of Application for Issuance of Shares to Specific Objects from China Securities Regulatory CommissionDec 2, 2025FinancingShanghai Stock Exchange
Announcement on Equity Change of Shareholder with Over 5% Shares Reaching 1% Scale and Result of Shareholding ReductionNov 26, 2025Other filingsShanghai Stock Exchange
Announcement on Resolutions of the 18th Meeting of the 3rd Board of DirectorsNov 19, 2025Meeting outcomeShanghai Stock Exchange
Announcement on Voluntary Disclosure on the Acceptance of Clinical Trial Application for Chiauranib Capsules for Treatment of Metastatic Pancreatic Ductal AdenocarcinomaNov 6, 2025Operations updateShanghai Stock Exchange
Announcement on Shareholding of Top 10 Shareholders and Top 10 Shareholders Without Sales Restrictions Concerning Share RepurchaseNov 5, 2025Other filingsShanghai Stock Exchange
Announcement on Non-compliance with Exercise Conditions in the 4th Exercise Period of 2021 Stock Appreciation Right Incentive Plan and Cancellation of This Part of Stock Appreciation RightsOct 31, 2025Other filingsShanghai Stock Exchange
Report for Q3 2025Oct 30, 2025Other filingsShanghai Stock Exchange
Announcement on Receiving Notice of Review Opinions from Shanghai Stock Exchange for Application for the Issuance of A-shares to Specific Objects in 2024Oct 29, 2025Other filingsShanghai Stock Exchange
Announcement on Convening the Q3 2025 Performance BriefingOct 24, 2025Meeting noticeShanghai Stock Exchange
Indicative Announcement on Equity Change of Shareholder with Over 5% Shares Reaching an Integral Multiple of 5% ScaleOct 16, 2025Ownership change noticeShanghai Stock Exchange
Indicative Announcement on Reply to Letter of Review and Inquiry on Application Documents for A-shares Issuance to Specific Objects in 2024Sep 24, 2025Other filingsShanghai Stock Exchange
Special Report on the Use of Previously Raised FundsSep 15, 2025Other filingsShanghai Stock Exchange
Announcement on Shareholding Reduction Plan for Shareholders with Over 5% SharesSep 10, 2025Other filingsShanghai Stock Exchange
Announcement on Resignation of Senior Management MemberSep 1, 2025Management or board changeShanghai Stock Exchange
2025 Semi-annual ReportAug 25, 2025Interim reportShanghai Stock Exchange
Announcement on Acceptance of Application for Issuance of A Shares to Specific Objects in 2024 by SSEAug 22, 2025Other filingsShanghai Stock Exchange
Announcement on Continuing to Use Temporarily Idle Raised Funds for Cash ManagementAug 18, 2025Other filingsShanghai Stock Exchange
Announcement on Convening the 2025 Semi-annual Performance BriefingAug 14, 2025Other filingsShanghai Stock Exchange
Announcement on Voluntary Disclosure of Semi-annual Earnings Preannouncement for 2025Jul 17, 2025Other filingsShanghai Stock Exchange
Announcement on Voluntary Disclosure of Top-line Analysis Data of Phase III Clinical Trial of Chidamide as the First-line Treatment for Diffuse Large B-cell LymphomaJul 9, 2025Other filingsShanghai Stock Exchange
Announcement on Abnormal Fluctuations in Stock TradingJul 3, 2025Other filingsShanghai Stock Exchange

Open Filings

Cap table

Built by 6ix from Shenzhen Chipscreen Biosciences Co. Ltd. Class A’s releases

Common shares
442,941,642
Fully diluted
442,941,642

Fully diluted

LineShares
Common shares442,941,642

Share count over time

CountShares
Nov 22, 2026442,941,642

Open Cap table

Shareholders

HolderSharesValueAs of
Vanguard Total International Stock Index Fund452KUS$1.77MJul 31, 2026
Vanguard Emerging Markets Stock Index Fund391KUS$1.53MJul 31, 2026
Vanguard Ftse All-World Ex-Us Small-Cap Index Fund105KUS$411KJul 31, 2026
The Emerging Markets Series19,685US$77,118Jul 31, 2026
Dimensional Emerging Markets Core Equity 2 ETF19,551US$76,601Jul 31, 2026
Dimensional Emerging Core Equity Market ETF10,594US$41,508Jul 31, 2026
Emerging Markets Social Core Equity Portfolio5,801US$22,726Jul 31, 2026
Dimensional World ex. U.S. Core Equity 2 ETF5,376US$21,063Jul 31, 2026
Vanguard ESG International Stock ETF4,848US$19,440May 31, 2026

Open Shareholders

Log in to ask 6ix AI your own questions about Shenzhen Chipscreen Biosciences Co. Ltd.